Coagulation factor assays from HYPHEN BioMed covering both immunodepleted plasma substrates for one-stage clotting assays and BIOPHEN™ chromogenic activity kits for specific factor quantification.
Factor assays are essential for diagnosing congenital bleeding disorders including hemophilia A (FVIII), hemophilia B (FIX), hemophilia C (FXI), Factor VII deficiency, Factor X deficiency, and Factor XIII deficiency, as well as monitoring factor concentrate therapy including extended half-life products.
Chromogenic methods provide assay results independent of lupus anticoagulants and other clotting interferences — the recommended approach for FVIII monitoring in patients on emicizumab (Hemlibra®).